vs
优尼威（CLMB）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是优尼威的1.1倍（$207.3M vs $182.4M），优尼威净利率更高（1.8% vs -62.0%，领先63.8%），优尼威同比增速更快（32.1% vs 25.9%），过去两年优尼威的营收复合增速更高（40.7% vs 38.0%）
优尼威解决方案是一家全球化学品与原料分销商，同时可为客户提供各类增值服务，在行业内拥有广泛的全球布局与专业服务能力。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CLMB vs RARE — 直观对比
营收规模更大
RARE
是对方的1.1倍
$182.4M
营收增速更快
CLMB
高出6.2%
25.9%
净利率更高
CLMB
高出63.8%
-62.0%
两年增速更快
CLMB
近两年复合增速
38.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $182.4M | $207.3M |
| 净利润 | $3.3M | $-128.6M |
| 毛利率 | 14.5% | — |
| 营业利润率 | 2.1% | -54.7% |
| 净利率 | 1.8% | -62.0% |
| 营收同比 | 32.1% | 25.9% |
| 净利润同比 | -9.5% | 3.5% |
| 每股收益（稀释后） | $0.18 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLMBRARE
| Q1 26 | $182.4M | — | ||
| Q4 25 | $193.8M | $207.3M | ||
| Q3 25 | $161.3M | $159.9M | ||
| Q2 25 | $159.3M | $166.5M | ||
| Q1 25 | $138.0M | $139.3M | ||
| Q4 24 | $161.8M | $164.6M | ||
| Q3 24 | $119.3M | $139.5M | ||
| Q2 24 | $92.1M | $147.0M |
净利润CLMBRARE
| Q1 26 | $3.3M | — | ||
| Q4 25 | $7.0M | $-128.6M | ||
| Q3 25 | $4.7M | $-180.4M | ||
| Q2 25 | $6.0M | $-115.0M | ||
| Q1 25 | $3.7M | $-151.1M | ||
| Q4 24 | $7.0M | $-133.2M | ||
| Q3 24 | $5.5M | $-133.5M | ||
| Q2 24 | $3.4M | $-131.6M |
毛利率CLMBRARE
| Q1 26 | 14.5% | — | ||
| Q4 25 | 15.4% | — | ||
| Q3 25 | 15.9% | — | ||
| Q2 25 | 16.5% | — | ||
| Q1 25 | 16.9% | — | ||
| Q4 24 | 19.3% | — | ||
| Q3 24 | 20.3% | — | ||
| Q2 24 | 20.2% | — |
营业利润率CLMBRARE
| Q1 26 | 2.1% | — | ||
| Q4 25 | 4.9% | -54.7% | ||
| Q3 25 | 4.3% | -106.9% | ||
| Q2 25 | 5.0% | -64.8% | ||
| Q1 25 | 3.5% | -102.6% | ||
| Q4 24 | 7.2% | -74.3% | ||
| Q3 24 | 7.1% | -94.6% | ||
| Q2 24 | 4.6% | -79.1% |
净利率CLMBRARE
| Q1 26 | 1.8% | — | ||
| Q4 25 | 3.6% | -62.0% | ||
| Q3 25 | 2.9% | -112.8% | ||
| Q2 25 | 3.7% | -69.0% | ||
| Q1 25 | 2.7% | -108.5% | ||
| Q4 24 | 4.3% | -80.9% | ||
| Q3 24 | 4.6% | -95.7% | ||
| Q2 24 | 3.7% | -89.5% |
每股收益（稀释后）CLMBRARE
| Q1 26 | $0.18 | — | ||
| Q4 25 | $1.51 | $-1.28 | ||
| Q3 25 | $1.02 | $-1.81 | ||
| Q2 25 | $1.30 | $-1.17 | ||
| Q1 25 | $0.81 | $-1.57 | ||
| Q4 24 | $1.52 | $-1.34 | ||
| Q3 24 | $1.19 | $-1.40 | ||
| Q2 24 | $0.75 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.8M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $118.4M | $-80.0M |
| 总资产 | $458.8M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLMBRARE
| Q1 26 | $41.8M | — | ||
| Q4 25 | $36.6M | $421.0M | ||
| Q3 25 | $49.8M | $202.5M | ||
| Q2 25 | $28.6M | $176.3M | ||
| Q1 25 | $32.5M | $127.1M | ||
| Q4 24 | $29.8M | $174.0M | ||
| Q3 24 | $22.1M | $150.6M | ||
| Q2 24 | $48.4M | $480.7M |
股东权益CLMBRARE
| Q1 26 | $118.4M | — | ||
| Q4 25 | $116.6M | $-80.0M | ||
| Q3 25 | $109.3M | $9.2M | ||
| Q2 25 | $105.2M | $151.3M | ||
| Q1 25 | $95.6M | $144.2M | ||
| Q4 24 | $90.6M | $255.0M | ||
| Q3 24 | $87.7M | $346.8M | ||
| Q2 24 | $79.8M | $432.4M |
总资产CLMBRARE
| Q1 26 | $458.8M | — | ||
| Q4 25 | $460.2M | $1.5B | ||
| Q3 25 | $376.1M | $1.2B | ||
| Q2 25 | $420.7M | $1.3B | ||
| Q1 25 | $370.1M | $1.3B | ||
| Q4 24 | $469.2M | $1.5B | ||
| Q3 24 | $371.9M | $1.5B | ||
| Q2 24 | $302.8M | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流CLMBRARE
| Q1 26 | — | — | ||
| Q4 25 | $-11.9M | $-99.8M | ||
| Q3 25 | $22.2M | $-91.4M | ||
| Q2 25 | $-2.2M | $-108.3M | ||
| Q1 25 | $8.5M | $-166.5M | ||
| Q4 24 | $16.0M | $-79.3M | ||
| Q3 24 | $-3.6M | $-67.0M | ||
| Q2 24 | $7.3M | $-77.0M |
自由现金流CLMBRARE
| Q1 26 | — | — | ||
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M |
自由现金流率CLMBRARE
| Q1 26 | — | — | ||
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% |
资本支出强度CLMBRARE
| Q1 26 | — | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% |
现金转化率CLMBRARE
| Q1 26 | — | — | ||
| Q4 25 | -1.70× | — | ||
| Q3 25 | 4.73× | — | ||
| Q2 25 | -0.37× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | 2.29× | — | ||
| Q3 24 | -0.66× | — | ||
| Q2 24 | 2.13× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLMB
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
